Business Wire

GCCA

Share
2021 “Concrete in Life” Global Photography Competition Launches – Focus on Sustainability, Beauty and Versatility of Concrete

The third annual GCCA “Concrete in Life” photography competition has today launched with a call for amateur and professional photographers from around the world to capture the role of concrete in their lives and its role in the sustainable world of tomorrow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005132/en/

Concrete plays a key role in supporting society around the world. Its durability, strength, resilience and boundless versatility means it can be used for nearly any application, while its properties such as thermal mass, recyclability and carbon uptake make it the most sustainable building material.

Judges include Isabel Allen, Editor at Architecture Today, Gian Luca Barone from Zaha Hadid Architects and experts from the Global Cement and Concrete Association (GCCA). They will be looking for entries showing concrete contributing to their individual lives and wider society, and notably sustainable buildings and infrastructure, to inspire the public in the run up to COP26, as the GCCA prepares to announce its detailed roadmap to zero carbon concrete.

Contestants are invited to capture imagery in the following categories, which include a brand new Sustainable Concrete category:

  • Urban design and use – images of the city landscapes and buildings around us, both well-known and hidden away
  • Infrastructure – photographs of our infrastructure, in our cities and rural, above and below ground
  • Concrete in daily life – the human side of concrete and how it’s used and interacted with daily
  • Sustainable Concrete – how concrete is used in sustainable construction, buildings and infrastructure such as wind farms, dams, green overpasses, wildlife crossings, green buildings

The competition crown one winner for the professional and amateur brackets of each category as well as one overall winner for the “Best Concrete in Life” photo of the year from the eight finalists. Each category winner will receive $2,500 in prize money, while the overall winner will receive $10,000.

Thomas Guillot, GCCA Chief Executive, said: “Being the world’s most used human-made product, concrete provides the foundation for so many lives. The competition is designed to capture that importance and demonstrate its versatility throughout society. Entries to the first two ‘Concrete in Life’ competitions from both professionals and amateurs were exceptional and managed to capture concrete’s strength, durability and resilience, and we’re so excited to be launching the third annual competition. We look forward to receiving a wide array of unique and inspiring entries from all over the world.”

The annual competition by the GCCA attracts tens of thousands of entries from professional and amateur photographers and challenges participants to capture photos that highlight the beauty of concrete and the vital role it plays in our society.

To enter the competition, participants should post a picture that they’ve taken on Instagram or Twitter using the hashtags #ConcreteInLife2021, #UrbanConcrete, #ConcreteInfrastructure, #ConcreteInDailyLife, and #SustainableConcrete. They should also tag the GCCA – @the.gcca on Instagram or @theGCCA on Twitter.

Winners will also be invited to speak about their images with the GCCA, with their images shared on GCCA’s website and social media channels.

Judging the entries are:

  • Gian Luca Barone, Senior Associate, Zaha Hadid Architects
  • John Fairley, Design Director, Curious Productions
  • Thomas Guillot, GCCA Chief Executive
  • Isabel Allen, Editor, Architecture Today

The competition will run until October 22nd 2021, with the winners announced during January 2022. Full competition details can be found at https://gccassociation.org/concreteinlife2021/

-ends-

About the GCCA:

Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye